5
In contrast to classical vaccine approaches, Immunovative’s allo-priming strategy addresses the phenomenon of viral evolution. In mid-May, for the first time, the company’s CEO Michael Har-Noy and colleagues presented a technology that might provide a universal anti-viral vaccine designed to protect immunocompromised humans and elderly adults from the current SARS-CoV-2 pandemic but also from any future novel virus outbreaks.
The vaccination concept appears more convincing than current vaccination approaches, which will last only for one year, according to AstraZeneca’s CEO Pascal Soriot. Patients will receive a series of injections of…